Client issue
A leading pharmaceutical company required support from CRA’s Life Sciences experts in developing a cross-functional ‘playbook’ to understand potential pricing challenges for pipeline combination assets and exploring strategic options to mitigate pricing risks.
CRA approach
We developed an in-depth market-specific landscape assessment and identified market archetypes to understand external P&MA processes likely to impact future combinations. The CRA team then identified combination scenarios representative of the client’s combination pipeline and explored analogues for each scenario to determine drivers of pricing outcomes. The output of this process was a risk assessment framework, which enabled development of mitigation strategies. We delivered a final playbook and roll-out workshop including strategies mapped to development stage and team function, and key sources of pricing risk.
Client impact
The outputs of this project provided a validated landscape analysis of combination therapy value, pricing and access frameworks, and a comprehensive risk assessment framework that enables identification of key sources of pricing risk for combination assets at global and local levels. It also delivered specific actionable mitigation strategies, including high-level implementation considerations (timing, feasibility requirements, and potential associated risks).
